Testicular germ cell tumors: Current concepts and management strategies

Minerva Urologica e Nefrologica

Volumn 65, Issue 2, 2013, Pages 133-155

  Cost, N G ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Germ Neoplasm staging; Testicular diseases Neoplasms

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN ALPHA SUBUNIT; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; LUTEINIZING HORMONE; TUMOR MARKER;

APOPTOSIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHORIOCARCINOMA; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DNA DAMAGE; EMBRYONAL CARCINOMA; FALSE NEGATIVE RESULT; GERM CELL TUMOR; HISTOLOGY; HUMAN; MALE FERTILITY; MINIMALLY INVASIVE PROCEDURE; MORBIDITY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REPRODUCTIVE PROCEDURE; REVIEW; SEMINOMA; TESTIS TERATOMA; TUMOR RECURRENCE; TUMOR VOLUME; YOLK SAC TUMOR;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 84879768363     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Bleyer A, O'Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Bethesda, MD: National Cancer Institute, NIH; 2006.
3. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010;19:1151-9.
4. Holmes L Jr, Escalante C, Garrison O, Foldi BX, Ogungbade GO, Essien EJ et al. Testicular cancer incidence trends in the USA (1975-2004): plateau or shifting racial paradigm? Public Health 2008;122:862-72.
5. Che M, Tamboli P, Ro JY, Park DS, Ro JS, Amato RJ et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer 2002;95:1228-33. (Pubitemid 35013056)
6. McGlynn ICA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003;97:63-70. (Pubitemid 36033864)
7. Molina Saera J, Aparicio Urtasun J, Diaz Beveridge R, Palomar Abad L, Gimenez Ortiz A, Ponce Lorenzo J et al. Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clin Transl Oncol 2006;8:588-93.
8. Lerro CC, Robbins AS, Fedewa SA, Ward EM. Disparities in stage at diagnosis among adults with tes-ticular germ cell tumors in the National Cancer Data Base. Urol Oncol 2013 [Epub ahead of print).
9. Wood HM, Elder JS. Cryptorchidism and testicular cancer: separating fact from fiction. J Urol 2009:181:452-61.
10. Greene MH, Kratz CP, Mai PL, Mueller C, Peters JA, Bratslavsky G et al. Familial testicular germ cell tu-mors in adults: 2010 summary of genetic risk fac-tors and clinical phenotype. Endocr Relat Cancer 2010;17:R109-21.
11. Brabrand S, Fossa SD, Cvancarova M, Axcrona U, Lehne G. Probability of metachronous testicular can-cer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer. J Clin Oncol 2012;30:4004-10.
12. Andreassen KE, Grotmol T, Cvancarova MS, Johan-nesen TB, Fossa SD. Risk of metachronous contralat-eral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). IntJ Cancer 2011;129:2867-74.
13. Akre O, Pettersson A, Richiardi L. Risk of contralat-eral testicular cancer among men with unilaterally undescended testis: a meta analysis. Int J Cancer 2009;124:687-9.
14. Nordsborg RB, Meliker JR, Wohlfahrt J, Melbye M, Raaschou-Nielsen O. Cancer in first-degree relatives and risk of testicular cancer in Denmark. IntJ Cancer 2011;129:2485-91.
15. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, Mc-Master ML, Gail MH et al. Risk of contralateral tes-ticular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-66. (Pubitemid 41417922)
16. Montironi R. Intratubular germ cell neoplasia of the testis: testicular intraepithelial neoplasia. Eur Urol 2002;41:651-4. (Pubitemid 35333923)
17. Risk MC, Masterson TA. Intratubular germ cell neo-plasms of the testis and bilateral testicular tumors: clinical significance and management options. In-dian J Urol 2010;26:64-71.
18. Kardias ME, Damjanov I, Holzbeierlein JM. ITGCN of the testis, contralateral testicular biopsy and bilateral testicular cancer. Urol Clin North Am 2007;34:119-25; abstract vii.
19. Meissner A, Mamoulakis C, de la Rosette JJ, Pes MP. Clinical update on testicular microlithiasis. Curr Opin Urol 2009;19:615-8.
20. Rajpert-de Meyts E, Hoei-Hansen CE. From gono-cytes to testicular cancer: the role of impaired gonad-al development. Ann N Y Acad Sei 2007;1120:168-80.
21. Looijenga LH, Zafarana G, Grygalewicz B, Summers-gill B, Debiec-Rychter M, Veltman J et al. Role of gain of 12p in germ cell tumour development. AP-MIS 2003;111:161-71; discussion 72-3.
22. Blomberg Jensen M, Leffers H, Petersen JH, Dau-gaard G, Skakkebaek NE, Rajpert-De Meyts E. As-sociation of the polymorphism of the CAG repeat in the mitochondrial DNA polymerase gamma gene (POLG) with testicular germ-cell cancer. Ann Oncol 2008;19:1910-4.
23. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009;41:811-5.
24. Schmelz HU, Port M, Stockinger M, Ruf C, Martinscheck A, Sparwasser C et al. Testis cancer cells have a genetic determination for a high sensitivity to apoptosis inducing stimuli. Urol Oncol 2010;28:49-58.
25. Mayer F, Honecker F, Looijenga LH, Bokemeyer C. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 2003;14:825-32. (Pubitemid 36827197)
26. Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP. Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 2013 [Epub ahead of print).
27. Stang A, Kuss O. Etiologic differences between seminoma and nonseminoma of the testis: a systematic review of epidemiologic studies. Hematol Oncol Clin North Am 2011;25:473-86, vii.
28. Weissbach L, Bussar-Maatz R, Mann K. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol 1997;32:16-22. (Pubitemid 27363871)
29. Carriere P, Baade P, Fritschi L. Population based incidence and age distribution of spermatocyte seminoma. J Urol 2007;178:125-8. (Pubitemid 46898471)
30. Aggarwal N, Parwani AV. Spermatocytic seminoma. Arch Pathol Lab Med 2009;133:1985-8.
31. Emerson RE, Ulbright TM. Morphological approach to tumours of the testis and paratestis. J Clin Pathol 2007;60:866-80. (Pubitemid 47234433)
32. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003;21:4092-9. (Pubitemid 46606175)
33. Worster A, Sharma S, Mookadam F, Opie J. Acute presentation of choriocarcinoma: a case study and review of the literature. CJEM 2002;4:111-4.
34. Cheville JC. Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am 1999;26:595-609. (Pubitemid 29411685)
35. Motzer RJ, Bosl GJ. Hemorrhage: a complication of metastatic testicular choriocarcinoma. Urology 1987;30:119-22. (Pubitemid 17132893)
36. Pohl HG, Shukla AR, Metcalf PD, Cilento BG, Retik AB, Bagli DJ et al. Prepubertal testis tumors: actual prevalence rate of histological types. J Urol 2004;172:2370-2. (Pubitemid 39507530)
37. Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med 2012;136:435-46.
38. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol 2005;18(Suppl 2):S51-60. (Pubitemid 40188617)
39. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42:553-62; discussion 62-3.
40. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112:232-46. (Pubitemid 10018961)
41. Moul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990;143:520-3. (Pubitemid 20108139)
42. Doherty FJ. Ultrasound of the nonacute scrotum. Semin Ultrasound CT MR 1991;12:131-56.
43. Carmignani L, Gadda F, Mancini M, Gazzano G, Nerva F, Rocco F et al. Detection of testicular ultrasonographic lesions in severe male infertility. J Urol 2004;172:1045-7. (Pubitemid 39096459)
44. Hashimoto K, Fujimoto H, Kouno T, Koseki M, Yonemori K, Hirata T et al. The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. Urol Oncol 2012;30:319-24.
45. Wanderas EH, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway 1955-1992. Eur J Cancer 1995;31A:2044-8. (Pubitemid 26024297)
46. Javadpour N. The role of biologic tumor markers in testicular cancer. Cancer 1980;45:1755-61. (Pubitemid 10153621)
47. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010;28:3388-404.
48. Horan G, Rafique A, Robson J, Dixon AK, Williams MV. CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer 2007;96:882-5. (Pubitemid 46452289)
49. See WA, Hoxie L. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 1993;150:874-8. (Pubitemid 23241288)
50. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K et al. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp 2012;36:127-45.
51. Gobel U, Schneider DT, Teske C, Schonberger S, Calaminus G. Brain metastases in children and adolescents with extracranial germ cell tumor data of the MAHO/MAKEI-registry. Klin Padiatr 2010;222:140-4.
52. Heidenreich A, Angerer-Shpilenya M. Organ-preserving surgery for testicular tumours. BJU Int 2012;109:474-90.
53. Katz MH, Eggener SE. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol 2009;27:477-83.
54. Hilton S. Contemporary radiological imaging of testicular cancer. BJU Int 2009;104:1339-45.
55. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997;169:521-5.
56. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99. (Pubitemid 39295027)
57. Aparicio J, Maroto P, del Muro XG, Guma J, Sanchez-Munoz A, Margeli M et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 2011;29:4677-81.
58. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52. (Pubitemid 35334756)
59. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
60. Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 2005;95:1197-200. (Pubitemid 40799429)
61. Chung P, Parker C, Panzarella T, Gospodarowicz MK, Jewett S, Milosevic MF et al. Surveillance in stage I testicular seminoma risk of late relapse. Can J Urol 2002;9:1637-40.
62. Robinson D, Moller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007;96:529-33. (Pubitemid 46215229)
63. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-8. (Pubitemid 350013842)
64. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65. (Pubitemid 41487803)
65. Oliver RT, Mead GM, Rustin GJ, JoffeJK, Aass N, Coleman R et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011;29:957-62.
66. Chung PW, Gospodarowicz MK, Panzarella T, Jewett MA, Sturgeon JF, Tew-George B et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004;45:754-59; discussion 9-60.
67. Garcia-del-Muro X, Maroto P, Guma J, Sastre J, Lopez Brea M, Arranz JA et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage ILA and HB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26:5416-21.
68. Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010;28:537-42.
69. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010;28:531-6.
70. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454-60. (Pubitemid 26051007)
71. Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860-2. (Pubitemid 27066267)
72. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975-9.
73. Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2003;169:2126-8. (Pubitemid 36576732)
74. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9. (Pubitemid 41095035)
75. Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET Eur J Cancer 1997;33:1234-41. (Pubitemid 27359642)
76. Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR et al. 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012;23:59-64.
77. Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M et al. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002;20:297-301. (Pubitemid 34032624)
78. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C. Advanced seminoma-treatment results and prognostic factors for survival after firstline, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 2003;98:745-52. (Pubitemid 36959270)
79. Ayash LJ, Clarke M, Silver SM, Braun T, Uberti J, Ratanatharathorn V et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant 2001;27:939-47. (Pubitemid 32529875)
80. Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 2005;173:824-9. (Pubitemid 40239350)
81. Leibovitch L, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759-63.
82. Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004;63:556-61.
83. Zuniga A, Kakiashvili D, Jewett MA. Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int 2009;104:1351-6.
84. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. (Pubitemid 350190758)
85. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009;181:627-32; discussion 32-3.
86. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 - the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25:1310-5. (Pubitemid 46706876)
87. Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II non-seminomatous germ cell tumors of the testis. J Urol 1984;131:677-80. (Pubitemid 14109615)
88. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393-6.
89. Rabbani F, Sheinfeld J, Farivar-Mohseni H, Leon A, Rentzepis MJ, Reuter VE et al. Low-volume nodal metastases detected at retroperitoneal lymphadenec tomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020-5. (Pubitemid 32702546)
90. Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, Bosl GJ. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and ILA nonseminomatous germ cell tumors. J Urol 2003;170:1159-62. (Pubitemid 37108102)
91. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:2781-8. (Pubitemid 46179468)
92. Vogelzang NJ, Fraley EE, Unge PH, Torkelson J, Levitt S, Kennedy BJ. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983;1:171-8. (Pubitemid 14245662)
93. Socinski MA, Garnick MB, Stomper PC, Fung CY, Richie JP. Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease. J Urol 1988;140:1437-41. (Pubitemid 19003194)
94. Behnia M, Foster R, Einhorn LH, Donohue J, Nichols CR. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer, the Indiana University experience. Eur J Can-cer 2000;36:472-5. (Pubitemid 30136224)
95. Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464-7. (Pubitemid 41079775)
96. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008;26:2966-72.
97. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106-13. (Pubitemid 26105516)
98. Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004;46:209-14; discussion 14-5.
99. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23. (Pubitemid 46594104)
100. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
101. Schmoll HJ, Jordan K, Huddart R, Uguna MP, Horwich A, Fizazi K et al. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):89-96.
102. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008;53:478-96.
103. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL et al. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:1038-58. (Pubitemid 44845492)
104. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111-3; discussion 4.
105. Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296-8. (Pubitemid 26081222)
106. Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007;25:5597-602.
107. Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582-94. (Pubitemid 30189828)
108. Foster RS, Baniel J, Leibovitch I, Curran M, Bihrle R, Rowland R et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 1996;155:1943-5.
109. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer 1999;83:856-9.
110. Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crepel M, Cloutier V et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology 2009;74:373-7.
111. Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ et al. Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology 2012;79:1079-84.
112. Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology 2012;79:156-9.
113. McGuire MS, Rabbani F, Mohseni H, Bains M, Motzer R, Sheinfeld J. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int 2003;91:469-73. (Pubitemid 36570562)
114. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007;25:1033-7. (Pubitemid 46596752)
115. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998;83:1409-19.
116. Alexandre J, Fizazi K, Mahe C, Culine S, Droz JP, Theodore C et al. Stage I non-seminomatous germcell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001;37:576-82. (Pubitemid 32261014)
117. Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006;94:820-7.
118. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA et al. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 2007;177:1330-4; discussion 4.
119. Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010;28:4906-11.
120. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 1997;8:531-8.
121. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 2005;23:423-30. (Pubitemid 41654511)
122. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000;164:381-4. (Pubitemid 30481930)
123. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74-80.
124. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997;8:41-7. (Pubitemid 27112801)
125. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008;26:5524-9.
126. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J et al. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000;11:553-9. (Pubitemid 30431377)
127. Gremmer R, Schroder ML, Ten Huinink WW, Brandsma D, Boogerd W. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 2008;90:335-9.
128. Raina V, Singh SP, Kamble N, Tanwar R, Rao K, Dawar R et al. Brain metastasis as the site of relapse in germ cell tumor of testis. Cancer 1993;72:2182-5. (Pubitemid 23280144)
129. Salvati M, Piccirilli M, Raco A, Santoro A, Frati R, Lenzi J et al. Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurg Rev 2006;29:130-7.
130. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80:1392-9. (Pubitemid 29308608)
131. Stone NN, Schlussel RN, Waterhouse RL, Unger P. Uparoscopic retroperitoneal lymph node dissection in stage A nonseminomatous testis cancer. Urology 1993;42:610-4. (Pubitemid 23347285)
132. Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 1992;148:1907-9; discussion 9-10.
133. Klotz L. Laparoscopic retroperitoneal lymphadenectomy for high-risk stage 1 nonseminomatous germ cell tumor: report of four cases. Urology 1994;43:752-6. (Pubitemid 24145626)
134. Janetschek G, Reissigl A, Peschel R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular tumor. Urology 1994;44:382-91. (Pubitemid 24273822)
135. Janetschek G, Hobisch A, Holtl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol 1996;156:89-93; discussion 4.
136. Gerber GS, Bissada NK, Hulbert JC, Kavoussi LR, Moore RG, Kantoff PW et al. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994;152:1188-91; discussion 91-2.
137. Neyer M, Peschel R, Akkad T, Springer-Stohr B, Berger A, Bartsch G et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol 2007;21:180-3. (Pubitemid 46446934)
138. Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler J. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int 2008;102:844-8.
139. Skolarus TA, Bhayani SB, Chiang HC, Brandes SB, Kibel AS, Undman J et al. Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer. J Endourol 2008;22:1485-9.
140. Nielsen ME, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk I et al. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I non-seminomatous germ cell testicular cancer. Urology 2007;70:1168-72. (Pubitemid 350297383)
141. Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol 2008;26:561-9.
142. Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol 2005;19:683-92; discussion 92.
143. Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, Stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol 2012 [Epub ahead of print].
144. Gardner MW, Roytman TM, Chen C, Brandes SB, Kibel AS, Grubb RL et al. Uparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update. J Endourol 2011;25:1753-7.
145. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-93. (Pubitemid 28175741)
146. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-40. (Pubitemid 32230862)
147. Culine S, Kramar A, Theodore C, Geoffrois L, Chevreau C, Biron P et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vin blastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008;26:421-7. (Pubitemid 351171694)
148. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009;101:1682-95.
149. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005;97:1580-8. (Pubitemid 41662712)
150. Rossen PB, Pedersen AF, Zachariae R, von der Maase H. Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol 2009;27:5993-9.
151. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99:533-44. (Pubitemid 47073556)
152. Richiardi L, Scelo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007;120:623-31. (Pubitemid 44969034)